非洛地平缓释片相关低钾血症

1例58岁男性患者因原发性高血压给予非洛地平缓释片5mg,1次/d;阿托伐他汀钙10mg,1次/d;维生素E0.1g,1次/d。3个月后血生化检查：K^＋3.11mmol/L。给予口服氯化钾缓释片,血钾恢复正常,但停用后又降低,遂入院。入院当日K^＋3.35mmol/L。经检查排除原发性醛固酮增多症所引起的低钾血症。停用非洛地平缓释片,改为厄贝沙坦0.15g,1次/d,并加用氯化钾缓释片0.5g,3次/d,其他治疗不变,2周后复查血生化示K^＋4.19mmol/L。停用氯化钾缓释片,1个月后K^＋3.85mmol/L,随后多次复查血钾均正常。

Hypokalemia associated with felodipine sustained-release tablets

A 58-year-old man with primary hypertension received felodipine sustained-release tablets 5 mg once daily,atorvastatin calcium 10 mg once daily,and vitamin E 0.1 g once daily. Three months later,his blood biochemical tests showed a serum potassium level of 3.11 mmol/L. The patient was given potassium chloride sustained-release tablets,and his serum potassium level returned to normal. However,the potassium level decreased again after drug discontinuation,and then he was hospitalized. On admission,his serum potassium level was 3.35 mmol/L. Hypokalemia due to primary aldosteronism was excluded. Felodipine sustained-release tablets were withdrawn and switched to irbesartan 0.15 g once daily. Potassium chloride sustained-release tablets 0.5 g thrice daily was added to the regimen,and other treatments continued. Two weeks later,his blood biochemical tests revealed a serum potassium level of 4.19 mmol/L. Potassium chloride sustained-release tablets were stopped and,one month later,his serum potassium level was 3.85 mmol/L. Subsequently,his serum potassium level was normal on reexaminations.